Default company panoramic image
6f9334bd c676 4e38 99bb 71a8e9a056dc


We’re developing protein-based tissue engineering strategies to drive skeletal regeneration by activating the body’s own bone forming cells.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Philadelphia, PA, USA
  • Currency USD
  • Founded November 2012
  • Website

Company Summary

Skelegen is a biotechnology company that is focused on the development of tissue engineering strategies to promote bone regeneration. The company was created based on the technology developed in Dr. Kurt Hankenson’s lab at the University of Pennsylvania in collaboration with his graduate student Michael Dishowitz. They utilize a protein called Jagged1 that induces differentiation of stem cells into osteoblasts, which are bone-producing cells.


  • Default avatar
    Kurt Hankenson

    Dr. Kurt Hankenson is an Associate Professor of Equine Musculoskeletal Research and Orthopaedic Surgery at the University of Pennsylvania. His lab is focused on understanding the signaling mechanisms that regulate osteoblast differentiation and bone formation and regeneration.

  • Default avatar
    Michael Dishowitz

    Michael Dishowitz is a doctoral graduate student in the Department of Bioengineering at the University of Pennsylvania. His research is focused on the development of tissue engineering strategies targeting cell signaling pathways to promote bone regeneration.

  • Default avatar
    University of Pennsylvania UPstart Program

    UPstart was created by the University of Pennsylvania's Center for Technology Transfer to work with scientists to commercialize technology developed within the Penn community. UPstart has helped its portfolio of companies obtain over $7.5 million in funding in the past two years. Members of UPstart, Michael Poisel and Dr. Dora Mitchell, are working closely with Skelegen providing general entrepreneurial expertise.